• Aithal, G.P., 2011. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol, 7, 139-150.

  • Cha, Y., Erez, T., Reynolds, I.J., Kumar, D., Ross, J., Koytiger, G., Kusko, R., Zeskind, B., Risso, S., Kagan, E., Papapetropoulos, S., Grossman, I.,Laifenfeld, D., 2018. Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol, 175, 168-180.

  • Chen, S., Ding, S., Yin, Y., Xu, L., Li, P., Peppelenbosch, M.P., Pan, Q.,Wang, W., 2019. Suppression of pyrimidine biosynthesis by targeting DHODH enzyme robustly inhibits rotavirus replication. Antiviral Res, 167, 35-44.

  • Debing, Y., Gisa, A., Dallmeier, K., Pischke, S., Bremer, B., Manns, M., Wedemeyer, H., Suneetha, P.V.,Neyts, J., 2014. A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients. Gastroenterology, 147, 1008-1011 e1007; quiz e1015-1006.

  • Debing, Y., Ramiere, C., Dallmeier, K., Piorkowski, G., Trabaud, M.A., Lebosse, F., Scholtes, C., Roche, M., Legras-Lachuer, C., De Lamballerie, X., Andre, P.,Neyts, J., 2016. Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity. J Hepatol, 65, 499-508.

  • Del Bello, A., Guilbeau-Frugier, C., Josse, A.G., Rostaing, L., Izopet, J.,Kamar, N., 2015. Successful treatment of hepatitis E virus-associated cryoglobulinemic membranoproliferative glomerulonephritis with ribavirin. Transpl Infect Dis, 17, 279-283.

  • Desai, A.N., Mohareb, A.M., Elkarsany, M.M., Desalegn, H., Madoff, L.C.,Lassmann, B., 2022. Viral Hepatitis E Outbreaks in Refugees and Internally Displaced Populations, sub-Saharan Africa, 2010-2020. Emerg Infect Dis, 28, 1074-1076.

  • Dhillon, S., 2021. Lonafarnib: First Approval. Drugs, 81, 283-289.

  • Dwek, R.A., Bell, J.I., Feldmann, M.,Zitzmann, N., 2022. Host-targeting oral antiviral drugs to prevent pandemics. Lancet, 399, 1381-1382.

  • European Association for the Study of the Liver. Electronic Address, E.E.E.,European Association for the Study of The, L., 2018. EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol, 68, 1256-1271.

  • Fox, R.J., Wiendl, H., Wolf, C., De Stefano, N., Sellner, J., Gryb, V., Rejdak, K., Bozhinov, P.S., Tomakh, N., Skrypchenko, I.,Muehler, A.R., 2022. A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis. Ann Clin Transl Neurol, 9, 977-987.

  • Guinault, D., Ribes, D., Delas, A., Milongo, D., Abravanel, F., Puissant-Lubrano, B., Izopet, J.,Kamar, N., 2016. Hepatitis E Virus-Induced Cryoglobulinemic Glomerulonephritis in a Nonimmunocompromised Person. Am J Kidney Dis, 67, 660-663.

  • Hooda, P., Chaudhary, M., Parvez, M.K., Sinha, N.,Sehgal, D., 2022. Inhibition of Hepatitis E Virus Replication by Novel Inhibitor Targeting Methyltransferase. Viruses, 14.

  • Ianevski, A., Giri, A.K.,Aittokallio, T., 2022. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res, 50, W739-W743.

  • Jones, S.W., Penman, S.L., French, N.S., Park, B.K.,Chadwick, A.E., 2021. Investigating dihydroorotate dehydrogenase inhibitor mediated mitochondrial dysfunction in hepatic in vitro models. Toxicol In Vitro, 72, 105096.

  • Kamar, N., Abravanel, F., Lhomme, S., Rostaing, L.,Izopet, J., 2015. Hepatitis E virus: chronic infection, extra-hepatic manifestations, and treatment. Clin Res Hepatol Gastroenterol, 39, 20-27.

  • Kamar, N., Del Bello, A., Abravanel, F., Pan, Q.,Izopet, J., 2022. Unmet Needs for the Treatment of Chronic Hepatitis E Virus Infection in Immunocompromised Patients. Viruses, 14.

  • Kamar, N., Izopet, J., Tripon, S., Bismuth, M., Hillaire, S., Dumortier, J., Radenne, S., Coilly, A., Garrigue, V., D'alteroche, L., Buchler, M., Couzi, L., Lebray, P., Dharancy, S., Minello, A., Hourmant, M., Roque-Afonso, A.M., Abravanel, F., Pol, S., Rostaing, L.,Mallet, V., 2014. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med, 370, 1111-1120.

  • Kamar, N., Marion, O., Abravanel, F., Izopet, J.,Dalton, H.R., 2016. Extrahepatic manifestations of hepatitis E virus. Liver Int, 36, 467-472.

  • Karki, P., Malik, S., Mallick, B., Sharma, V.,Rana, S.S., 2016. Massive Hemolysis Causing Renal Failure in Acute Hepatitis E Infection. J Clin Transl Hepatol, 4, 345-347.

  • Kaushik, N., Subramani, C., Anang, S., Muthumohan, R., Shalimar, Nayak, B., Ranjith-Kumar, C.T.,Surjit, M., 2017. Zinc Salts Block Hepatitis E Virus Replication by Inhibiting the Activity of Viral RNA-Dependent RNA Polymerase. J Virol, 91.

  • Kinast, V., Burkard, T.L., Todt, D.,Steinmann, E., 2019. Hepatitis E Virus Drug Development. Viruses, 11.

  • Kitrinos, K.M., Corsa, A., Liu, Y., Flaherty, J., Snow-Lampart, A., Marcellin, P., Borroto-Esoda, K.,Miller, M.D., 2014. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology, 59, 434-442.

  • Li, P., Li, Y., Wang, Y., Liu, J., Lavrijsen, M., Li, Y., Zhang, R., Verstegen, M.M.A., Wang, Y., Li, T.C., Ma, Z., Kainov, D.E., Bruno, M.J., De Man, R.A., Van Der Laan, L.J.W., Peppelenbosch, M.P.,Pan, Q., 2022. Recapitulating hepatitis E virus-host interactions and facilitating antiviral drug discovery in human liver-derived organoids. Sci Adv, 8, eabj5908.

  • Li, P., Liu, J., Li, Y., Su, J., Ma, Z., Bramer, W.M., Cao, W., De Man, R.A., Peppelenbosch, M.P.,Pan, Q., 2020. The global epidemiology of hepatitis E virus infection: A systematic review and meta-analysis. Liver Int, 40, 1516-1528.

  • Luthra, P., Naidoo, J., Pietzsch, C.A., De, S., Khadka, S., Anantpadma, M., Williams, C.G., Edwards, M.R., Davey, R.A., Bukreyev, A., Ready, J.M.,Basler, C.F., 2018. Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses. Antiviral Res, 158, 288-302.

  • Mcbride, J.T., 1985. Ribavirin and RSV: a new approach to an old disease. Pediatr Pulmonol, 1, 294-295.

  • Muehler, A., Kohlhof, H., Groeppel, M.,Vitt, D., 2020a. Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects. Eur J Drug Metab Pharmacokinet, 45, 557-573.

  • Muehler, A., Peelen, E., Kohlhof, H., Groppel, M.,Vitt, D., 2020b. Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis. Mult Scler Relat Disord, 43, 102129.

  • Netzler, N.E., Enosi Tuipulotu, D., Vasudevan, S.G., Mackenzie, J.M.,White, P.A., 2019. Antiviral Candidates for Treating Hepatitis E Virus Infection. Antimicrob Agents Chemother, 63.

  • Pedroni, L., Dellafiora, L., Varra, M.O., Galaverna, G.,Ghidini, S., 2022. In silico study on the Hepatitis E virus RNA Helicase and its inhibition by silvestrol, rocaglamide and other flavagline compounds. Sci Rep, 12, 15512.

  • Pischke, S., Hartl, J., Pas, S.D., Lohse, A.W., Jacobs, B.C.,Van Der Eijk, A.A., 2017. Hepatitis E virus: Infection beyond the liver? J Hepatol, 66, 1082-1095.

  • Qu, C., Xu, L., Yin, Y., Peppelenbosch, M.P., Pan, Q.,Wang, W., 2017. Nucleoside analogue 2'-C-methylcytidine inhibits hepatitis E virus replication but antagonizes ribavirin. Arch Virol, 162, 2989-2996.

  • Roessler, H.I., Knoers, N., Van Haelst, M.M.,Van Haaften, G., 2021. Drug Repurposing for Rare Diseases. Trends Pharmacol Sci, 42, 255-267.

  • Shukla, P., Nguyen, H.T., Faulk, K., Mather, K., Torian, U., Engle, R.E.,Emerson, S.U., 2012. Adaptation of a genotype 3 hepatitis E virus to efficient growth in cell culture depends on an inserted human gene segment acquired by recombination. J Virol, 86, 5697-5707.

  • Therapeutics, P.-I., https://imux.com/pipeline/.

  • U.S. Fda, 2010. FDA Drug Safety Communication: New boxed warning for severe liver injury with arthritis drug Arava (leflunomide). www.fda.gov/drugs. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-new-boxed-warning-severe-liver-injury-arthritis-drug-arava-leflunomide

  • U.S. Fda, 2012. FDA Approved Labeling Text - NDA 20292. www.fda.gov/drugs. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202992s000lbl.pdfVehreschild, M., Atanasov, P., Yurko, K., Oancea, C., Popov, G., Smesnoi, V., Placinta, G., Kohlhof, H., Vitt, D., Peelen, E., Mihajlovic, J.,Muehler, A.R., 2022. Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial. Infect Dis Ther, 11, 2159-2176.

  • Velavan, T.P., Pallerla, S.R., Johne, R., Todt, D., Steinmann, E., Schemmerer, M., Wenzel, J.J., Hofmann, J., Shih, J.W.K., Wedemeyer, H.,Bock, C.T., 2021. Hepatitis E: An update on One Health and clinical medicine. Liver Int, 41, 1462-1473.

  • Wagoner, J., Herring, S., Hsiang, T.Y., Ianevski, A., Biering, S.B., Xu, S., Hoffmann, M., Pohlmann, S., Gale, M., Jr., Aittokallio, T., Schiffer, J.T., White, J.M.,Polyak, S.J., 2022. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2. Microbiol Spectr, 10, e0333122.

  • Wang, B., Mahsoub, H.M., Li, W., Heffron, C.L., Tian, D., Hassebroek, A.M., Leroith, T.,Meng, X.J., 2023. Ribavirin Treatment Failure-Associated Mutation, Y1320H, in the RNA-Dependent RNA Polymerase of Genotype 3 Hepatitis E Virus (HEV) Enhances Virus Replication in a Rabbit HEV Infection Model. mBio, 14, e0337222.

  • Wang, Y., Wang, W., Xu, L., Zhou, X., Shokrollahi, E., Felczak, K., Van Der Laan, L.J., Pankiewicz, K.W., Sprengers, D., Raat, N.J., Metselaar, H.J., Peppelenbosch, M.P.,Pan, Q., 2016. Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication. Antimicrob Agents Chemother, 60, 2834-2848.

  • Wang, W., Cui, J., Ma, H., Lu, W., Huang, J. 2021. Targeting Pyrimidine Metabolism in the Era of Precision Cancer Medicine. Frontiers in Oncol, 11, 684961.

  • Webb, G.W.,Dalton, H.R., 2019. Hepatitis E: an underestimated emerging threat. Ther Adv Infect Dis, 6, 2049936119837162.

  • Xiong, R., Zhang, L., Li, S., Sun, Y., Ding, M., Wang, Y., Zhao, Y., Wu, Y., Shang, W., Jiang, X., Shan, J., Shen, Z., Tong, Y., Xu, L., Chen, Y., Liu, Y., Zou, G., Lavillete, D., Zhao, Z., Wang, R., Zhu, L., Xiao, G., Lan, K., Li, H.,Xu, K., 2020. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. Protein Cell, 11, 723-739.